99 related articles for article (PubMed ID: 17660484)
1. Modeling of in vitro drug activity and prediction of clinical outcome in acute myeloid leukemia.
Quartino A; Karlsson MO; Freijs A; Jonsson N; Nygren P; Kristensen J; Lindhagen E; Larsson R
J Clin Pharmacol; 2007 Aug; 47(8):1014-21. PubMed ID: 17660484
[TBL] [Abstract][Full Text] [Related]
2. In vitro short-term sensitivity test for the prediction of response to chemotherapy in acute non-lymphocytic leukemia.
Saccardi R; Bernabei PA; Bezzini R; Agostino FC; Leoni F; Rossi Ferrini P
Chemioterapia; 1988 Jun; 7(3):173-8. PubMed ID: 3168072
[TBL] [Abstract][Full Text] [Related]
3. Prediction of individual response to chemotherapy in patients with acute myeloid leukaemia using the chemosensitivity index Ci.
Staib P; Staltmeier E; Neurohr K; Cornely O; Reiser M; Schinköthe T
Br J Haematol; 2005 Mar; 128(6):783-91. PubMed ID: 15755281
[TBL] [Abstract][Full Text] [Related]
4. Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias.
Shiozawa K; Nakanishi T; Tan M; Fang HB; Wang WC; Edelman MJ; Carlton D; Gojo I; Sausville EA; Ross DD
Clin Cancer Res; 2009 Mar; 15(5):1698-707. PubMed ID: 19223502
[TBL] [Abstract][Full Text] [Related]
5. Induction chemotherapy for acute myelogenous leukemia.
Kalaycio M
Curr Hematol Rep; 2005 Jan; 4(1):49-50. PubMed ID: 15610659
[No Abstract] [Full Text] [Related]
6. Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission.
Stone RM; DeAngelo DJ; Janosova A; Galinsky I; Canning C; Ritz J; Soiffer RJ
Am J Hematol; 2008 Oct; 83(10):771-7. PubMed ID: 18756547
[TBL] [Abstract][Full Text] [Related]
7. The prognostic significance of leukemic cells clearance kinetics evaluation during the initial course of induction therapy with HAD (homoharringtonine, cytosine arabinoside, daunorubicin) in patients with de novo acute myeloid leukemia.
Xiao Z; Xue H; Li R; Zhang L; Yu M; Hao Y
Am J Hematol; 2008 Mar; 83(3):203-5. PubMed ID: 17874451
[TBL] [Abstract][Full Text] [Related]
8. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
Hołowiecki J; Grosicki S; Kyrcz-Krzemien S; Skotnicki AB; Piatkowska-Jakubas B; Warzocha K; Seferynska I; Zdziarska B
Ann Hematol; 2008 May; 87(5):361-7. PubMed ID: 18074133
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia.
Li GY; Liu JZ; Zhang B; Wang LX; Wang CB; Chen SG
Biomed Pharmacother; 2009 Sep; 63(8):566-70. PubMed ID: 19095404
[TBL] [Abstract][Full Text] [Related]
10. P-glycoprotein (Pgp) modulation in untreated acute myeloid leukemia (AML): Cancer and Leukemia Group B (CALGB) trials in younger and older adults.
Kolitz JE; George SL; Baer MR; Lee EJ; Bloomfield CD; Larson RA;
Ann Hematol; 2004; 83 Suppl 1():S103-4. PubMed ID: 15124695
[No Abstract] [Full Text] [Related]
11. All-trans retinoic acid in association with low dose cytosine arabinoside in the treatment of acute myeoid leukemia in elderly patients.
Di Febo A; Laurenti L; Falcucci P; Tosti ME; Fianchi L; Pagano L; Leone G
Am J Ther; 2007; 14(4):351-5. PubMed ID: 17667210
[TBL] [Abstract][Full Text] [Related]
12. Growth response of residual leukemia after initial drug therapy.
Karp JE; Burke PJ
Cancer Res; 1986 Aug; 46(8):4205-7. PubMed ID: 3731087
[TBL] [Abstract][Full Text] [Related]
13. Scheduling-dependent interaction for the combination of cytosine arabinoside and daunorubicin on HL-60 cells.
Bernabei PA; Rombolà G; Saccardi R; Bezzini R; Santini V; Pifferi C; Gattei V; Ferrini PR
Haematologica; 1988; 73(6):466-70. PubMed ID: 3148508
[No Abstract] [Full Text] [Related]
14. Effect of cloretazine (VNP40101M) on acute myeloid leukaemia blast cells in vitro as a single agent and combined with cytarabine and daunorubicin.
Morris KL; Adams JA; Liu Yin JA
Leuk Res; 2009 Aug; 33(8):1096-9. PubMed ID: 19268363
[TBL] [Abstract][Full Text] [Related]
15. [Results of the treatment of myeloblastic crisis in myelocytic leukemia using the HAR program].
Zdziechowska H; Niemierko E; Takiel M; Konopka L; Pawelski S
Acta Haematol Pol; 1986; 17(3-4):91-5. PubMed ID: 3473887
[No Abstract] [Full Text] [Related]
16. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
Liu J; Mi Y; Fu M; Yu W; Wang Y; Lin D; Bian S; Wang J
Am J Hematol; 2009 Jul; 84(7):422-7. PubMed ID: 19484734
[TBL] [Abstract][Full Text] [Related]
17. Nodular regenerative hyperplasia: a cause of ascites and hepatomegaly after chemotherapy for leukemia.
Rosen AA; Iseri O; Fishbein G; Knodell RG
Am J Gastroenterol; 1991 Jan; 86(1):86-8. PubMed ID: 1986559
[TBL] [Abstract][Full Text] [Related]
18. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
Camera A; Rinaldi CR; Palmieri S; Cantore N; Mele G; Mettivier V; Miraglia E; Mastrullo L; Grimaldi F; Luciano L; Guerriero A; Rotoli B; Ferrara F
Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
[TBL] [Abstract][Full Text] [Related]
19. Modeling the pharmacodynamics of highly schedule-dependent agents: exemplified by cytarabine-based regimens in acute myeloid leukemia.
Braess J; Fiegl M; Lorenz I; Waxenberger K; Hiddemann W
Clin Cancer Res; 2005 Oct; 11(20):7415-25. PubMed ID: 16243815
[TBL] [Abstract][Full Text] [Related]
20. Drastic effect of cell density on the cytotoxicity of daunorubicin and cytosine arabinoside.
Masquelier M; Vitols S
Biochem Pharmacol; 2004 May; 67(9):1639-46. PubMed ID: 15081863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
